cancer
heterogen
diseas
mark
aberr
cellular
growth
remain
one
lead
caus
mortal
unit
state
last
sever
year
shown
increas
incid
nation
center
health
statist
center
diseas
control
prevent
improv
made
standard
treatment
regimen
solid
tumor
includ
gammaknif
surgeri
radiationandor
chemotherapi
surviv
rate
vari
wide
tumor
type
individu
patient
exampl
case
pancreat
tumor
median
surviv
less
month
despit
aggress
standard
therapi
greenle
et
al
wherea
tumor
overal
surviv
rate
greater
year
prostat
cancer
nation
center
health
statist
center
diseas
control
prevent
addit
resist
radiationandor
chemotherapi
well
metastat
spread
advanc
tumor
complic
treatment
diseas
prognosi
therefor
need
remain
newer
altern
therapi
would
applic
mani
solid
tumor
type
would
efficaci
set
advanc
tumor
develop
genet
epigenet
alter
tumor
cell
enhanc
resist
earli
advanc
molecular
biolog
enabl
scientist
sequenc
clone
gene
field
gene
therapi
emerg
rational
treat
diseas
replac
manipul
supplement
nonfunct
gene
numer
basic
preclin
studi
lead
first
clinic
trial
rosenberg
et
al
use
ex
vivo
gene
therapi
retrovirus
treat
metastat
melanoma
enthusiasm
gene
therapi
strategi
cancer
remain
high
nearli
twothird
current
clinic
gene
therapi
trial
direct
cancer
edelstein
et
al
emerg
data
clinic
gene
therapi
trial
brought
light
contribut
numer
variabl
success
end
result
note
factor
includ
gene
target
regul
cell
transduct
effici
durat
gene
express
vector
stabil
allow
readministr
optim
factor
therebi
minim
variabl
choic
vector
deliveri
system
remain
crucial
wide
use
vector
remain
adenoviru
recent
increas
use
adenoassoci
viru
aav
nonvir
deliveri
system
howev
use
approach
often
necessit
intratumor
local
inject
attempt
deliv
vector
system
met
poor
result
one
basic
tenet
system
target
first
cellular
layer
circul
agent
would
encount
endotheli
line
blood
vessel
introduct
vascular
target
genedeliveri
vehicl
could
permit
higher
local
concentr
transduct
increas
exposur
minim
system
toxic
review
focus
therapeut
concept
target
cancer
gene
therapi
vector
suitabl
sitedirect
deliveri
method
identifi
suitabl
receptor
liganddirect
deliveri
complex
tissu
tumor
microenviron
permit
number
differ
target
strategi
toward
differ
cell
type
relev
therapi
abund
genet
abnorm
tumor
cell
present
clear
target
genet
manipul
addit
introduct
gene
genet
stabl
cellular
compon
tumor
stroma
endotheli
cell
blood
vessel
provid
altern
strategi
deliveri
anoth
approach
involv
stimul
immun
system
tumor
growth
inhibit
advantag
disadvantag
method
along
current
concept
target
gene
explor
follow
section
intens
studi
area
immunolog
last
decad
made
cancer
immunobiolog
one
promis
domin
approach
cancer
gene
therapi
blankenstein
et
al
goal
stimul
host
respons
tumor
enhanc
induc
nativ
immun
system
use
direct
vaccin
immun
tumor
antigen
enhanc
immunogen
tumor
transfect
individu
tumor
cell
autolog
vaccin
emerg
success
method
gene
deliveri
tumor
cell
transfect
number
candid
gene
use
type
treatment
gene
express
costimul
tcell
activ
eg
vesoski
hurwitz
cytokin
eg
granulocytemacrophag
colonystimul
factor
gmcsf
tumor
necrosi
factor
tnf
interferon
facilit
differenti
andor
activ
effector
cell
qian
et
al
allogen
mhc
class
protein
eg
transfect
tumor
patient
nabel
et
al
syngen
mhc
class
ii
protein
whose
express
enabl
tumor
cell
present
antigen
tlymphocyt
stimul
activ
thelper
cell
hock
et
al
introduct
gene
permit
activ
target
tumor
cell
elimin
strategi
led
sever
phase
iii
trial
includ
melanoma
patient
autolog
vaccin
irradi
transduc
tumor
cell
direct
adenovir
deliveri
antigen
jgenem
differ
approach
use
immun
protocol
genedeliveri
vector
express
known
tumor
antigen
surfac
muscl
cell
dendrit
cell
tlymphocyt
cell
turn
stimul
antigenpres
cell
secondari
stimulatori
cell
activ
immun
respons
import
consider
approach
avoid
sensit
nontumor
cell
antigen
use
select
stimul
antigen
express
embryon
tissu
protect
immun
surveil
eg
cancertesti
antigen
intracellular
protein
acr
et
al
gunther
et
al
surprisingli
type
immunomodul
strategi
use
highli
depend
goal
treatment
select
ideal
treatment
regimen
requir
consider
number
factor
type
immun
desir
antibodymedi
versu
cellmedi
respons
requir
stimul
differ
subset
tlymphocyt
durat
respons
potent
shortterm
treatment
may
desir
elimin
residu
tumor
cell
goal
prevent
metastas
growth
recurr
longterm
respons
need
induc
condit
patient
immun
respons
strategi
describ
reli
function
patient
immunesystem
patient
immun
compromis
tumor
chemotherapyradi
therapi
immunomodul
therapi
may
possibl
tumor
antigen
order
immun
protocol
tumor
antigen
success
immun
agent
need
valid
express
might
verifi
individu
patient
consider
addit
type
cancer
select
treatment
essenti
success
immunomodul
gene
therapi
patient
increas
understand
immun
respons
particularli
cancer
patient
molecular
mediat
influenc
activ
suppress
futur
success
gene
therapi
approach
may
improv
concept
suicidegen
treatment
modal
introduc
nearli
year
ago
emerg
standalon
treatment
modal
genedirect
enzym
prodrug
therapi
gdept
concept
use
inact
prodrug
convert
activ
cytotox
drug
enzymat
reaction
within
cell
convert
enzym
deliv
agent
tumor
site
subsequ
express
cellular
machineri
sitespecif
deliveri
drugconvert
enzym
tumor
site
result
high
local
accumul
cytotox
drug
mediat
tumor
elimin
littletono
accumul
drug
elsewher
moreov
local
convers
cytotox
drug
also
lead
potent
bystand
effect
complet
tumor
erad
achiev
littl
transduct
tumor
mass
aghi
et
al
rooseboom
et
al
wide
use
prototyp
exampl
herp
simplex
viru
thymidin
kinas
hsvtk
combin
ganciclovir
activ
hsvtk
phosphoryl
ganciclovir
gener
toxic
speci
eck
et
al
moolten
et
al
treatment
strategi
leverag
numer
gene
therapi
trial
includ
direct
intratumor
inject
primari
brain
tumor
intraperiton
inject
ovarian
cancer
patient
anoth
exampl
express
bacteri
cytosin
deaminas
convert
enzym
combin
system
deliv
transfect
cell
convert
lead
cytotox
effect
crystal
et
al
ohwada
et
al
one
overrid
advantag
two
prototyp
system
use
clinic
readi
prodrug
gener
therapeut
effect
therebi
streamlin
approv
regulatori
agenc
avoid
complic
delay
clinic
translat
although
establish
malign
caus
singl
protein
gene
dysregul
sever
promin
genet
pathway
common
cancer
two
common
dysregul
transcript
activ
oncogen
transcript
silenc
tumor
suppressor
gene
thu
obviou
strategi
would
treat
tumor
genet
alter
replac
overexpress
silenc
suppressor
gene
silenc
activ
oncogen
clear
advantag
therapeut
strategi
specif
neoplast
cell
tumor
cell
principl
cell
mutat
would
occur
unfortun
unlik
gdept
strategi
would
bystand
effect
necessit
extrem
high
gene
transfer
effici
within
tumor
eg
nearli
erad
number
class
tumor
suppressor
transcript
silenc
gene
includ
proapoptot
gene
fasligand
trail
bax
norri
et
al
gene
involv
cellcycl
regul
prb
kang
et
al
howev
wide
studi
tumor
suppressor
guardian
genom
mutat
delet
half
human
tumor
singl
allel
loss
often
suffici
singl
hit
twohit
hypothesi
tumorigenesi
sinc
function
cell
cycl
apoptosi
hypothesi
replac
overexpress
could
serv
extrem
effect
therapi
levin
inde
inject
recombin
human
adenoviru
express
trademark
gendicin
tm
becam
world
first
gene
therapi
product
approv
government
agenc
state
food
drug
administr
china
sfda
treatment
cancer
mileston
field
gene
therapi
pave
way
translat
effort
peng
silenc
activ
oncogen
achiev
use
antisens
ribozym
rnaibas
therapi
silenc
techniqu
reli
differ
mechan
action
net
effect
blockag
mrna
translat
protein
cancer
biolog
follow
class
gene
target
oncogen
cellcycl
regulatori
gene
drugresist
gene
angiogen
gene
growth
factor
receptor
gene
gene
cell
signal
pathway
lebedeva
stein
mccaffrey
et
al
scanlon
scanlon
et
al
singer
et
al
stein
techniqu
earli
preclin
phase
progress
great
enthusiasm
work
pioneer
late
judah
folkman
becom
wellknown
fact
tumor
requir
vascular
suppli
grow
beyond
critic
size
realiz
introduc
field
angiogenesi
cancer
biolog
brought
antiangiogenesi
therapi
viabl
new
strategi
treat
diseas
antiangiogenesi
treatment
seek
elimin
inhibit
vascular
expans
reduc
tumor
burden
number
natur
gener
inhibitor
angiogenesi
studi
gene
therapi
modal
includ
angiostatin
endostatin
puduv
altern
downregul
secret
proangiogen
factor
vegf
bfgf
via
silenc
hypoxia
induc
alpha
within
tumor
shown
reduc
tumor
burden
preclin
model
folkman
nesbit
gene
therapi
strategi
focus
endotheli
cell
introduc
new
cellular
target
exploit
present
uniqu
advantag
therapeut
target
tumor
cell
despit
popul
densiti
far
less
tumor
cell
endotheli
cell
principl
transduc
gene
act
within
singl
cell
would
enhanc
effect
surround
tumor
cell
akin
bystand
effect
howev
approach
also
intrins
pose
sever
uniqu
challeng
small
cellular
contribut
tumor
popul
creat
difficulti
deliveri
effici
like
low
intratumor
inject
addit
antiangiogen
strategi
also
rais
challeng
select
gene
target
tumor
cell
possess
genet
epigenet
alter
provid
ration
target
intervent
howev
endotheli
cell
line
tumor
blood
vessel
larg
consid
epigenet
stabl
therefor
select
silenc
inhibitori
product
would
affect
normal
cell
throughout
bodi
transfect
rais
risk
unwant
side
effect
therapeut
gene
deliveri
cancer
also
result
enhanc
standard
treatmentregimen
efficaci
major
modern
chemotherapi
discrimin
normal
cancer
cell
cytotox
prolifer
normal
cell
hematopoiet
precursor
cell
becom
doselimit
treatment
chemotherapeut
thu
method
reduc
toxic
normal
cell
would
major
advanc
treatment
regimen
exampl
bone
marrow
deplet
remain
major
side
effect
chemotherapi
transfect
bone
marrow
cell
multidrugresist
gene
enhanc
cellular
resist
chemotherapi
allow
patient
receiv
higher
dose
convent
agent
culver
huber
margrath
lattim
gerson
mickisch
et
al
templeton
lasic
anoth
recent
suggest
approach
synergist
therapi
introduct
iodin
transport
tumor
cell
gene
deliveri
transport
increas
uptak
radioact
iodin
approach
demonstr
success
treatment
experiment
thyroid
tumor
boelaert
franklyn
expans
tumor
type
use
preclin
therapi
imag
purpos
strategi
make
use
replic
recombin
virus
underli
concept
administ
viru
intratumor
viral
replic
take
place
transduc
cell
infect
cell
ultim
disrupt
viral
progeni
releas
allow
spread
infect
import
achiev
cancerspecif
replic
limit
viral
replic
site
tumor
vecil
lang
accomplish
select
cell
entri
select
transcript
gene
necessari
replic
tumor
tissuespecif
promot
delet
gene
necessari
replic
normal
cell
tumor
cell
eg
delet
clinic
gene
therapi
trial
made
clear
success
control
sever
variabl
one
import
genedeliveri
system
dictat
type
cell
therapeut
gene
transfer
express
level
therapeut
gene
durat
express
fundament
challeng
gene
deliveri
origin
fact
dna
charg
natur
unstabl
biolog
environ
cross
biolog
barrier
intact
endothelium
cell
nuclear
membran
addit
target
ligand
bind
uniqu
cellsurfac
receptor
lead
improv
specif
gene
transfer
cell
express
target
receptor
challeng
identifi
ligand
suffici
high
affin
target
identifi
cellsurfac
receptor
either
uniqu
display
increas
surfac
densiti
target
tissu
anoth
requir
ligandtarget
deliveri
vehicl
get
intern
recogn
target
receptor
receptormedi
endocytosi
make
sure
plasmid
dna
get
deliv
intracellularli
genedeliveri
system
divid
two
gener
categori
biolog
system
engin
virus
chemic
system
lipidand
polymerbas
nanoparticl
mah
et
al
thoma
klibanov
walther
stein
zhdanov
et
al
viral
genedeliveri
system
genet
engin
nonrepl
virus
capabl
infect
cell
deliv
genom
contain
therapeut
gene
viral
genom
integr
host
genom
retroviru
lentiviru
later
stage
aav
exist
episom
adenoviru
earli
stage
aav
infect
bramson
park
carter
page
dano
gener
recogn
viral
vector
effect
gene
transfer
vehicl
howev
chemic
genedeliveri
system
provid
attract
altern
viral
vector
due
low
immunogen
lack
replic
risk
rel
eas
manufactur
larg
scale
thoma
klibanov
zhdanov
et
al
moreov
abil
incorpor
target
ligand
specif
home
target
tissu
littl
effect
manufactur
one
major
advantag
chemic
genedeliveri
system
anwer
et
al
driessen
et
al
wood
et
al
chang
viral
tropism
attempt
well
bune
et
al
krasnykh
et
al
rie
et
al
wickham
et
al
howev
modif
involv
alter
viral
structur
protein
often
problemat
inactiv
endogen
viral
ligandvir
receptor
interact
replac
new
ligand
roelvink
et
al
integr
sitespecif
system
target
vector
high
genedeliveri
profil
would
creat
power
system
wide
therapeut
diagnost
applic
potenti
allevi
need
invas
procedur
recent
describ
develop
new
class
hybrid
genedeliveri
vector
incorpor
genet
element
bacteri
mammalian
virus
singl
entiti
hajit
et
al
soghomonyan
et
al
exploit
genet
element
recombin
aav
improv
mammalian
cell
gene
express
element
afford
sitespecif
target
bacteriophag
phage
creat
novel
hybrid
viru
term
aavp
proofofconcept
studi
aavp
target
rgdcontain
motif
arginineglycineaspart
acid
home
alphavintegrin
gener
carri
hsvtk
gene
cassett
suitabl
imag
gdept
treatment
regimen
vector
retain
target
specif
alphavintegrin
mediat
rgd
motif
retain
high
transduct
effici
vitro
vivo
rgdaavp
mediat
strong
accumul
within
tumor
follow
system
administr
strong
transgen
express
evid
day
inject
furthermor
demonstr
clinic
applic
imag
feau
could
integr
specif
monitor
tempor
dynam
spatial
heterogen
transgen
express
time
positron
emiss
tomographi
pet
lastli
observ
robust
reduct
tumor
burden
murin
mammari
tumor
immunocompet
mice
well
numer
human
tumor
xenograft
immunocompromis
anim
follow
administr
ganciclovir
hajit
et
al
soghomonyan
et
al
taken
togeth
data
introduc
novel
hybrid
vector
may
appli
mani
diseas
set
target
gene
therapi
subsequ
studi
work
target
aavp
vector
expand
success
employ
altern
transgen
well
multipl
model
human
diseas
soft
tissu
sarcoma
clinic
standard
determin
patient
respons
often
correl
poorli
patient
outcom
proofofconcept
target
aavp
vector
carri
hsvtk
suicid
gene
investig
altern
mean
assess
tumor
respons
therapi
hajit
et
al
evalu
transgen
express
pet
imag
provid
platform
repeatedli
monitor
local
magnitud
gene
express
therebi
predict
respons
therapi
ganciclovir
similarli
target
aavp
vector
deliv
altern
transgen
tumor
necrosi
factoralpha
tnf
explor
preclin
model
melanoma
recent
spontan
cancer
dog
compar
oncolog
trial
consortium
nation
cancer
institut
paoloni
et
al
tandl
et
al
final
studi
mechan
aavp
vector
target
vasculaturemedi
tumor
therapi
implic
heterotyp
bystand
kill
effect
endotheli
celltumor
cell
interact
larg
mediat
intercellular
gap
junction
involv
connexin
trepel
et
al
present
much
work
involv
target
aavp
vector
model
human
diseas
howev
integr
clinic
applic
pet
imag
feau
therapi
ganciclovir
suggest
rapid
translat
patient
popul
may
immin
furthermor
improv
transgen
regul
develop
tissuespecif
promot
may
enhanc
tissu
specif
improv
therapeut
index
vector
develop
new
vasculatur
occur
embryon
develop
normal
physiolog
process
number
patholog
diseas
includ
solid
tumor
coordin
multistag
process
term
angiogenesi
involv
local
releas
growthpromot
factor
subsequ
stimul
endotheli
cell
line
blood
vessel
activ
endotheli
cell
migrat
prolifer
invad
surround
tissu
support
expans
tumor
cell
beyond
critic
size
folkman
folkman
et
al
mustonen
alitalo
addit
well
establish
angiogen
endotheli
cell
line
tumor
blood
vessel
morpholog
molecularli
distinct
arap
et
al
pasqualini
et
al
repertoir
cellsurfac
molecul
angiogen
blood
vessel
often
exist
new
express
molecul
normal
present
quiescent
endotheli
cell
ii
elev
level
protein
normal
found
cell
surfac
iii
rearrang
cellsurfac
molecul
lumin
ablumin
surfac
differenti
express
pattern
suggest
opportun
sitespecif
target
angiogen
vasculatur
ozawa
et
al
challeng
field
howev
identif
valid
system
access
molecul
suffici
specif
express
mediat
target
number
techniqu
appli
effort
genom
approach
reli
express
differ
tumor
endothelium
compar
normal
blood
vessel
st
croix
et
al
util
microdissect
combin
serial
analysi
gene
express
sage
identifi
sever
candid
tumor
endotheli
marker
human
colorect
cancer
saha
et
al
st
croix
et
al
work
demonstr
feasibl
genet
analys
cellular
subpopul
includ
endotheli
cell
robust
potenti
identifi
target
moreov
similar
studi
sinc
ensu
includ
gener
express
sequenc
tag
est
analysi
cdna
microarray
identifi
candid
must
valid
viabl
protein
also
must
local
cell
surfac
contribut
system
target
due
inher
limit
genet
screen
proteom
screen
often
provid
greater
evid
relev
function
signific
target
beyond
deriv
protein
array
cellular
homogen
techniqu
directli
profil
cell
surfac
endotheli
cell
recent
emerg
includ
vivo
screen
system
inject
biotin
deriv
twodimension
peptid
map
roesli
et
al
b
scheurer
et
al
recent
report
describ
proofofconcept
analys
silico
bioinformaticsbas
identif
peptid
inhibit
endotheli
cell
prolifer
migrat
karagianni
popel
group
extens
experi
identif
access
target
angiogen
vasculatur
use
vivo
phage
display
kolonin
et
al
phage
display
highli
versatil
technolog
involv
genet
manipul
bacteriophag
peptid
antibodi
express
surfac
smith
petrenko
strategi
reveal
vascular
address
system
allow
tissuespecif
target
normal
blood
vessel
angiogenesisrel
target
tumor
blood
vessel
vascular
receptor
correspond
select
peptid
identifi
blood
vessel
normal
organ
tumor
blood
vessel
strategi
shown
possibl
shed
light
select
express
biolog
relev
target
within
special
vascular
bed
vivo
phage
display
procedur
phage
capabl
home
certain
organ
tumor
follow
intraven
inject
recov
phage
display
peptid
librari
abil
individu
peptid
target
tissu
also
analyz
method
pasqualini
et
al
brief
phage
propag
pilusposit
bacteria
lyse
phage
rather
secret
multipl
copi
phage
display
particular
insert
phage
bound
target
molecul
elut
amplifi
grow
host
bacteria
multipl
round
biopan
perform
popul
select
binder
obtain
addit
higher
throughput
approach
higher
stringenc
also
develop
enhanc
approach
phage
librari
biopan
vivo
screen
number
organ
parallel
kolonin
et
al
amino
acid
sequenc
recov
peptid
determin
sequenc
dna
correspond
insert
phage
genom
ultim
approach
allow
circul
home
peptid
detect
unbias
function
assay
without
preconceiv
notion
natur
target
asid
carrier
function
target
gene
deliveri
peptid
may
use
drug
discoveri
lead
peptidomimet
drug
therapeut
modul
correspond
receptor
given
receptor
identifi
biochem
genet
approach
bind
properti
peptid
librari
also
verifi
human
mous
cell
line
tissu
kolonin
et
al
biopan
strategi
vivo
intact
cell
sever
advantag
first
oppos
purifi
receptor
membranebound
protein
like
preserv
function
conform
lost
upon
purif
immobil
outsid
context
intact
cell
second
mani
cellsurfac
receptor
requir
cell
membran
environ
function
homoor
heterodimer
interact
may
occur
third
combinatori
approach
allow
select
cell
membran
ligand
unbias
function
assay
without
preconceiv
notion
natur
cellular
receptor
repertoir
thu
unknown
receptor
target
relat
methodolog
numer
normal
murin
tissuespecif
vascular
marker
angiogenesisrel
molecul
tumor
blood
vessel
identifi
even
human
patient
gener
ligandreceptor
pair
identifi
group
receptor
angiogen
protein
adhes
molecul
metabol
receptor
extracellular
matrix
compon
stressrespons
molecul
see
tabl
interestingli
identifi
marker
also
serv
viral
receptor
alphavintegrin
receptor
adenoviru
wickham
et
al
receptor
coronavirus
look
et
al
yeager
et
al
shown
receptor
echovirus
pulli
et
al
tempt
specul
bacteriophag
vegf
vascular
endotheli
growth
factor
bfgf
basic
fibroblast
growth
factor
mcam
melanoma
cell
adhes
molecul
ec
endotheli
cell
hmwmaa
high
molecular
weight
melanomaassoci
antigen
mmp
matrix
metalloproteinas
crkl
chicken
tumor
regul
kinaselik
protein
hsp
heat
shock
protein
wat
white
adipos
tissu
vcam
vascular
cell
adhes
molecul
class
prokaryot
virus
could
use
cellular
receptor
eukaryot
virus
given
specif
target
peptid
moieti
natur
host
bacteriophag
eukaryot
viru
vastli
differ
structur
phage
capsid
protein
provid
good
evid
bacteriophag
share
ancestri
anim
virus
evolutionari
biolog
footnot
find
suggest
receptor
isol
vivo
phage
display
cell
intern
capabl
key
featur
one
wish
util
peptid
motif
gene
therapi
carrier
target
specif
cell
subpopul
one
hallmark
event
cancer
progress
angiogenesi
chapter
describ
uniqu
characterist
angiogen
tumor
vasculatur
exploit
deliv
gene
specif
effici
explor
variou
therapeut
gene
therapi
strategi
method
uncov
vascular
zipcod
prolifer
endothelium
describ
ligandreceptor
pair
discov
technolog
use
target
genedeliveri
vehicl
also
highlight
new
hybrid
genedeliveri
vector
aavp
shown
antitumor
efficaci
multipl
anim
model
tumor
subtyp
conclus
vasculartarget
strategi
cancer
gene
therapi
may
becom
new
treatment
paradigm
improv
enhanc
current
therapeut
protocol
